Recurring Software Licensing ModelA licensing/subscription plus services model creates recurring revenue and customer stickiness common in enterprise life-science software. Over a multi-month horizon this supports predictability of revenue and upsell opportunities (support, training, modules), which can stabilize cash flow as adoption deepens.

Specialized Omics Analytics ProductA focused, domain-specific platform for omics data gives Qlucore a durable competitive position in high-barrier technical workflows. Specialized tools that integrate into research and diagnostics tend to have stickier customers, higher switching costs and sustained structural demand as omics data generation grows.

Low Financial LeverageVery modest debt levels reduce near-term refinancing and interest burdens, giving the company more financial flexibility. With ongoing losses, low leverage lessens default risk and preserves optionality for restructuring, R&D prioritization, or measured capital raises over the coming months.

Bears Say

Declining Revenue And Negative Gross ProfitRevenue contraction combined with negative gross profit signals that core product economics no longer cover direct costs. This is a structural red flag: unless pricing, product mix or cost base is addressed, gross-margin erosion will continue to undermine long-term profitability and the ability to scale sustainably.

Persistent Negative Cash FlowContinued negative operating and free cash flow, and a material TTM FCF decline, create funding risk and limit reinvestment capacity. Over a multi-month horizon this constrains product development, sales expansion and increases likelihood of dilutive financing if profitability and cash conversion are not restored.

Sustained Operating Losses And Equity ErosionLarge, persistent losses that erode shareholders' equity weaken the balance sheet and reduce resilience to shocks. This diminishes the firm's ability to absorb setbacks or invest in growth, and raises the probability of future capital raises that could dilute existing holders if profitability is not achieved.

QCORE FAQ

What was Qlucore AB’s price range in the past 12 months?

Qlucore AB lowest stock price was kr0.25 and its highest was kr1.93 in the past 12 months.

What is Qlucore AB’s market cap?

Currently, no data Available

When is Qlucore AB’s upcoming earnings report date?

Qlucore AB’s upcoming earnings report date is Jun 17, 2026 which is in 103 days.

How were Qlucore AB’s earnings last quarter?

Qlucore AB released its earnings results on Feb 26, 2026. The company reported -kr0.077 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.077.

Is Qlucore AB overvalued?

According to Wall Street analysts Qlucore AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Qlucore AB pay dividends?

Qlucore AB does not currently pay dividends.

What is Qlucore AB’s EPS estimate?

Qlucore AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Qlucore AB have?

Qlucore AB has 42,900,500 shares outstanding.

What happened to Qlucore AB’s price movement after its last earnings report?

Qlucore AB reported an EPS of -kr0.077 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.752%.

Which hedge fund is a major shareholder of Qlucore AB?

Currently, no hedge funds are holding shares in SE:QCORE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Qlucore AB

Qlucore AB (publ) provides bioinformatics data analysis tools for research and precision diagnostics in Sweden and internationally. Its products include Qlucore Omics Explorer, a bioinformatics AI software for research in life science, biotech, food, and plant industries, as well as academia; Qlucore Diagnostics, a software platform for multi-omics companion and precision diagnostics; and Qlucore Insights, a software for clinical data analysis. Qlucore AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.